These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24936645)

  • 21. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of
    Liang S; Zhou X; Pan H; Yang Y; Shi L; Wang L
    Hematology; 2019 Dec; 24(1):613-622. PubMed ID: 31482762
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis.
    Qin Y; Shen K; Liu T; Ma H
    BMC Cancer; 2023 Jun; 23(1):527. PubMed ID: 37291515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients.
    Shivarov V; Gueorguieva R; Stoimenov A; Tiu R
    Leuk Res; 2013 Nov; 37(11):1445-50. PubMed ID: 23962568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNMT3A mutations in acute myeloid leukemia.
    Ley TJ; Ding L; Walter MJ; McLellan MD; Lamprecht T; Larson DE; Kandoth C; Payton JE; Baty J; Welch J; Harris CC; Lichti CF; Townsend RR; Fulton RS; Dooling DJ; Koboldt DC; Schmidt H; Zhang Q; Osborne JR; Lin L; O'Laughlin M; McMichael JF; Delehaunty KD; McGrath SD; Fulton LA; Magrini VJ; Vickery TL; Hundal J; Cook LL; Conyers JJ; Swift GW; Reed JP; Alldredge PA; Wylie T; Walker J; Kalicki J; Watson MA; Heath S; Shannon WD; Varghese N; Nagarajan R; Westervelt P; Tomasson MH; Link DC; Graubert TA; DiPersio JF; Mardis ER; Wilson RK
    N Engl J Med; 2010 Dec; 363(25):2424-33. PubMed ID: 21067377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
    Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
    Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
    Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
    Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
    Walter MJ; Ding L; Shen D; Shao J; Grillot M; McLellan M; Fulton R; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Kandoth C; Baty J; Westervelt P; DiPersio JF; Mardis ER; Wilson RK; Ley TJ; Graubert TA
    Leukemia; 2011 Jul; 25(7):1153-8. PubMed ID: 21415852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
    Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
    Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients.
    Park SH; Choi JC; Kim SY; Yi J; Oh SH; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
    Biomed Res Int; 2015; 2015():723682. PubMed ID: 25650308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNMT3A mutations in Chinese childhood acute myeloid leukemia.
    Li W; Cui L; Gao C; Liu S; Zhao X; Zhang R; Zheng H; Wu M; Li Z
    Medicine (Baltimore); 2017 Aug; 96(31):e7620. PubMed ID: 28767575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
    LaRochelle O; Bertoli S; Vergez F; Sarry JE; Mansat-De Mas V; Dobbelstein S; Dastugue N; Strzelecki AC; Cavelier C; Creancier L; Pillon A; Kruczynski A; Demur C; Sarry A; Huguet F; Huynh A; Récher C; Delabesse E
    Oncotarget; 2011 Nov; 2(11):850-61. PubMed ID: 22081665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.
    Shen Y; Zhu YM; Fan X; Shi JY; Wang QR; Yan XJ; Gu ZH; Wang YY; Chen B; Jiang CL; Yan H; Chen FF; Chen HM; Chen Z; Jin J; Chen SJ
    Blood; 2011 Nov; 118(20):5593-603. PubMed ID: 21881046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia.
    Jost E; Lin Q; Weidner CI; Wilop S; Hoffmann M; Walenda T; Schemionek M; Herrmann O; Zenke M; Brümmendorf TH; Koschmieder S; Wagner W
    Leukemia; 2014 Jun; 28(6):1227-34. PubMed ID: 24280869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.
    Yuan XQ; Zhang DY; Yan H; Yang YL; Zhu KW; Chen YH; Li X; Yin JY; Li XL; Zeng H; Chen XP
    Oncotarget; 2016 Sep; 7(37):60555-60574. PubMed ID: 27528035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNMT3A R882 mutation is associated with elevated expression of MAFB and M4/M5 immunophenotype of acute myeloid leukemia blasts.
    Yang L; Liu Y; Zhu L; Xiao M
    Leuk Lymphoma; 2015; 56(10):2914-22. PubMed ID: 25721756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NRAS
    Pan L; Liang F; Chen X; Hao Z; Muyey DM; Chen X; Wang H
    Ann Clin Lab Sci; 2023 May; 53(3):389-397. PubMed ID: 37437942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.